Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG

Overview

Journal Neurosci Bull

Specialty Neurology

Date 2019 May 2

PMID 31041694

Citations 7

Authors

Ling Fang

Xinmei Kang

Zhen Wang

Shisi Wang

Jingqi Wang

Yifan Zhou

Chen Chen

Xiaobo Sun

Yaping Yan

Allan G Kermode

Lisheng Peng

Wei Qiu

Affiliations

Soon will be listed here.

Abstract

Immunoglobulin G against myelin oligodendrocyte glycoprotein (MOG-IgG) is detectable in neuromyelitis optica spectrum disorder (NMOSD) without aquaporin-4 IgG (AQP4-IgG), but its pathogenicity remains unclear. In this study, we explored the pathogenic mechanisms of MOG-IgG in vitro and in vivo and compared them with those of AQP4-IgG. MOG-IgG-positive serum induced complement activation and cell death in human embryonic kidney (HEK)-293T cells transfected with human MOG. In C57BL/6 mice and Sprague-Dawley rats, MOG-IgG only caused lesions in the presence of complement. Interestingly, AQP4-IgG induced astroglial damage, while MOG-IgG mainly caused myelin loss. MOG-IgG also induced astrocyte damage in mouse brains in the presence of complement. Importantly, we also observed ultrastructural changes induced by MOG-IgG and AQP4-IgG. These findings suggest that MOG-IgG directly mediates cell death by activating complement in vitro and producing NMOSD-like lesions in vivo. AQP4-IgG directly targets astrocytes, while MOG-IgG mainly damages oligodendrocytes.

Citing Articles

FLAMES overlaying anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review.

Zhong R, Chen X, Liao F, Lin Z, Zhang Z, Chen Y BMC Neurol. 2024; 24(1):140.

PMID: 38664672 PMC: 11044310. DOI: 10.1186/s12883-024-03617-z.

Evolution in anti-myelin oligodendrocyte glycoprotein antibody detection and its clinical significance: a narrative review.

Zhong X, Wang Y, Luo W, Ma X, Sun X, Jiang B Ann Transl Med. 2023; 11(7):287.

PMID: 37090054 PMC: 10116431. DOI: 10.21037/atm-20-4547.

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.

Lin L, Wu Y, Hang H, Lu J, Ding Y Front Immunol. 2022; 13:853891.

PMID: 35898513 PMC: 9309329. DOI: 10.3389/fimmu.2022.853891.

Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics.

Gavriilaki M, Kimiskidis V, Gavriilaki E Pharmaceuticals (Basel). 2020; 13(11).

PMID: 33114553 PMC: 7693884. DOI: 10.3390/ph13110341.

Treatment of MOG antibody associated disorders: results of an international survey.

Whittam D, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O J Neurol. 2020; 267(12):3565-3577.

PMID: 32623595 PMC: 7954658. DOI: 10.1007/s00415-020-10026-y.

References

Ratelade J, Verkman A . Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica. Mol Immunol. 2014; 62(1):104-13. PMC: 4306420. DOI: 10.1016/j.molimm.2014.06.003. View

OConnor K, McLaughlin K, De Jager P, Chitnis T, Bettelli E, Xu C . Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007; 13(2):211-7. PMC: 3429369. DOI: 10.1038/nm1488. View

Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W . Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A. 2006; 103(50):19057-62. PMC: 1748176. DOI: 10.1073/pnas.0607242103. View

Tradtrantip L, Yao X, Su T, Smith A, Verkman A . Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol. 2017; 134(1):35-44. PMC: 5600280. DOI: 10.1007/s00401-017-1734-6. View

Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K . Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016; 59(12):1270-1281. PMC: 5101174. DOI: 10.1007/s11427-015-4997-y. View

Hamid S, Whittam D, Mutch K, Linaker S, Solomon T, Das K . What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017; 264(10):2088-2094. PMC: 5617862. DOI: 10.1007/s00415-017-8596-7. View

Parratt J, Prineas J . Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler. 2010; 16(10):1156-72. DOI: 10.1177/1352458510382324. View

Pandit L, Nakashima I, Mustafa S, Takahashi T, Kaneko K . Anti Myelin Oligodendrocyte Glycoprotein associated Immunoglobulin G (AntiMOG-IgG)-associated Neuromyelitis Optica Spectrum Disorder with Persistent Disease Activity and Residual Cognitive Impairment. Ann Indian Acad Neurol. 2017; 20(4):411-413. PMC: 5682748. DOI: 10.4103/aian.AIAN_250_17. View

Li A, Zhang J, Xie W, Strong J, Zhang J . Inflammatory Changes in Paravertebral Sympathetic Ganglia in Two Rat Pain Models. Neurosci Bull. 2017; 34(1):85-97. PMC: 5799124. DOI: 10.1007/s12264-017-0142-1. View

10.

Linington C, Bradl M, Lassmann H, Brunner C, Vass K . Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 1988; 130(3):443-54. PMC: 1880661. View

11.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-89. PMC: 4515040. DOI: 10.1212/WNL.0000000000001729. View

12.

Weil M, Mobius W, Winkler A, Ruhwedel T, Wrzos C, Romanelli E . Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases. Cell Rep. 2016; 16(2):314-322. PMC: 4949381. DOI: 10.1016/j.celrep.2016.06.008. View

13.

Dale R, Tantsis E, Merheb V, Kumaran R, Sinmaz N, Pathmanandavel K . Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm. 2014; 1(1):e12. PMC: 4202678. DOI: 10.1212/NXI.0000000000000012. View

14.

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V . Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016; 87(9):1005-15. PMC: 5013123. DOI: 10.1136/jnnp-2015-312601. View

15.

Fang X, Sun D, Wang Z, Yu Z, Liu W, Pu Y . MiR-30a Positively Regulates the Inflammatory Response of Microglia in Experimental Autoimmune Encephalomyelitis. Neurosci Bull. 2017; 33(6):603-615. PMC: 5725374. DOI: 10.1007/s12264-017-0153-y. View

16.

von Budingen H, Hauser S, Fuhrmann A, Nabavi C, Lee J, Genain C . Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci U S A. 2002; 99(12):8207-12. PMC: 123046. DOI: 10.1073/pnas.122092499. View

17.

Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C . Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A. 2003; 100(16):9446-51. PMC: 170938. DOI: 10.1073/pnas.1133443100. View

18.

Saadoun S, Waters P, Owens G, Bennett J, Vincent A, Papadopoulos M . Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun. 2014; 2:35. PMC: 3977893. DOI: 10.1186/2051-5960-2-35. View

19.

Brehm U, Piddlesden S, Gardinier M, Linington C . Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol. 1999; 97(1-2):9-15. DOI: 10.1016/s0165-5728(99)00010-7. View

20.

Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T . Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009; 386(4):623-7. DOI: 10.1016/j.bbrc.2009.06.085. View